"This recombinant (genetically engineered) protein vaccine will be considered for active immunisation to prevent COVID-19 caused by SARS-CoV-2. If approved, a complete course of the Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 vaccine is potentially two doses given as an intramuscular injection 3 weeks apart.
"Protein vaccines use a non-infectious component of the coronavirus. This protein is found on the surface of the virus and is manufactured in a laboratory, in the case of this product using insect cells. When the vaccine enters the body, immune cells recognise the vaccine protein as foreign and launch an immune response against it."
Thoughts?
No comments:
Post a Comment